Lacticaseicin 30 and Colistin as a Promising Antibiotic Formulation against Gram-Negative β-Lactamase-Producing Strains and Colistin-Resistant Strains
Antimicrobial resistance is a global health concern across the world and it is foreseen to swell if no actions are taken now. To help curbing this well announced crisis different strategies are announced, and these include the use of antimicrobial peptides (AMP), which are remarkable molecules known...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2021-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Antimicrobial resistance is a global health concern across the world and it is foreseen to swell if no actions are taken now. To help curbing this well announced crisis different strategies are announced, and these include the use of antimicrobial peptides (AMP), which are remarkable molecules known for their killing activities towards pathogenic bacteria. Bacteriocins are ribosomally synthesized AMP produced by almost all prokaryotic lineages. Bacteriocins, unlike antibiotics, offer a set of advantages in terms of cytotoxicity towards eukaryotic cells, their mode of action, cross-resistance and impact of microbiota content. Most known bacteriocins are produced by Gram-positive bacteria, and specifically by lactic acid bacteria (LAB). LAB-bacteriocins were steadily reported and characterized for their activity against genetically related Gram-positive bacteria, and seldom against Gram-negative bacteria. The aim of this study is to show that lacticaseicin 30, which is one of the bacteriocins produced by <i>Lacticaseibacillus paracasei</i> CNCM I-5369, is active against Gram-negative clinical strains (<i>Salmonella</i> <i>enterica</i> Enteritidis H10, <i>S. enterica</i> Typhimurium H97, <i>Enterobacter cloacae</i> H51, <i>Escherichia coli</i> H45, <i>E. coli</i> H51, <i>E. coli</i> H66, <i>Klebsiella oxytoca</i> H40, <i>K. pneumoniae</i> H71, <i>K. variicola</i> H77, <i>K. pneumoniae</i> H79, <i>K. pneumoniae</i> H79), whereas antibiotics failed. In addition, lacticaseicin 30 and colistin enabled synergistic interactions towards the aforementioned target Gram-negative clinical strains. Further, the combinations of lacticaseicin 30 and colistin prompted a drastic downregulation of <i>mcr-1</i> and <i>mcr-9</i> genes, which are associated with the colistin resistance phenotypes of these clinical strains. This report shows that lacticaseicin 30 is active against Gram-negative clinical strains carrying a rainbow of <i>mcr</i> genes, and the combination of these antimicrobials constitutes a promising therapeutic option that needs to be further exploited. |
|---|---|
| Item Description: | 10.3390/antibiotics11010020 2079-6382 |